Our Orascovery technology is based on the novel P-gp pump inhibitor molecule, encequidar, formerly known as HM30181A. Oral administration of encequidar in combination with established chemotherapy agents such as paclitaxel, irinotecan, docetaxel, and eribulin has been shown in our clinical studies to date to improve the absorption of these agents by blocking the P-gp pump in the intestinal wall. Oral paclitaxel and encequidar, formerly known as Oraxol (“Oral Paclitaxel”), is our lead asset in our Orascovery platform. We are also advancing several clinical candidates for the treatment of solid tumors on this platform: oral irinotecan and encequidar, formerly known as Oratecan (“Oral Irinotecan”); oral docetaxel and encequidar, formerly known as Oradoxel (“Oral Docetaxel”); and oral eribulin and encequidar, formerly known as Eribulin ORA (“Oral Eribulin”).

Oral paclitaxel and encequidar

Paclitaxel is a widely used IV administered tubulin-stabilizing chemotherapeutic agent.
Clinical data from our Phase III study demonstrated both a better efficacy and better tolerability profile among patients. Oral paclitaxel and encequidar has completed a Phase 3 pivotal trial in metastatic breast cancer, with several additional on-going clinical studies as monotherapy and in combination with other proven chemotherapy agents.

Oral docetaxel and encequidar

Docetaxel is a chemotherapy agent, mainly administered via IV administration to patients with breast, lung, prostate, gastric, and head and neck cancers.

Oral docetaxel and encequidar is ready to advance to Phase 2.

Oral irinotecan and encequidar

Irinotecan is a chemotherapy agent, mainly administered via IV administration to patients with metastatic colorectal cancer (mCRC), and is administered to a lesser extent to patients with glioblastoma, lung, ovarian, cervical, upper gastrointestinal and pancreatic cancers.

Oral irinotecan and encequidar is ready to advance to Phase 2.

Oral eribulin and encequidar

Eribulin is a chemotherapy agent, mainly administered via IV to patients with breast cancer and liposarcoma.. Intravenous eribulin (Halaven®) is approved by the FDA and is marketed by the Eisai Company.

Oral eribulin and encequidar is currently in Phase 1.